Financial impact of ivabradine on reducing heart failure penalties under the Hospital Readmission Reduction Program. (1st February 2017)

• Record Type: Journal Article
• Authors: Kansal, Anuraag R.; Krotneva, Stanimira; Tafazzoli, Ali; Patel, Harshali K.; Borer, Jeffrey S.; Böhm, Michael; Komajda, Michel; Maya, Juan; Tavazzi, Luigi; Ford, Ian; Kielhorn, Adrian
• Is Part Of: Current medical research and opinion. Volume 33:Number 2(2017)
• Page Start: 185
• Page End: 191
• Publication Date: 2017-02-01
• Subjects: Heart failure -- hospital readmission reduction program (HRRP) -- ivabradine -- readmission penalties -- readmissions; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2016.1248381
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: The introduction of the Hospital Readmission Reduction Program (HRRP) has led to renewed interest in developing strategies to reduce 30 day readmissions among patients with heart failure (HF). In this study, a model was developed to investigate whether the addition of ivabradine to a standard-of-care (SoC) treatment regimen for patients with HF would reduce HRRP penalties incurred by a hypothetical hospital with excess 30 day readmissions. Research design: A model using a Monte Carlo simulation framework was developed. Model inputs included national hospital characteristics, hospital-specific characteristics, and the ivabradine treatment effect as quantified by a post hoc analysis of the Systolic Heart failure treatment with the If inhibitor ivabradine Trial (SHIFT). Results: The model computed an 83% reduction in HF readmission penalty payments in a hypothetical hospital with a readmission rate of 22.95% (excess readmission ratio = 1.056 over the national average readmission rate of 21.73%), translating into net savings of $44, 016. A sensitivity analysis indicated that the readmission penalty is affected by the specific characteristics of the hospital, including the readmission rate, size of the ivabradine-eligible population, and ivabradine utilization. Conclusions: The results of this study indicate that the addition of ivabradine to an SoC treatment regimen for patients with HF may lead to a reduction in the penalties incurred by hospitals under the HRRP. This highlights the role ivabradine can play as part of a wider effort to optimize the care of patients with HF.